Daiichi Sankyo and Merck, two leading pharmaceutical companies, have entered into a partnership to develop and commercialize a lung cancer drug. The deal, valued at $22 billion, aims to utilize the strengths of both companies to bring innovative treatments to patients. Under the agreement, Daiichi Sankyo will receive an upfront payment and potential milestone payments based on the achievement of predetermined targets. Merck will have exclusive rights to market and distribute the drug globally. This collaboration represents a significant advancement in the fight against cancer and showcases the importance of strategic partnerships in the pharmaceutical industry.